Genscript flags 2025 loss on Legend impairment despite surge in licensing profit

Genscript Biotech ( (HK:1548) ) just unveiled an update.

Genscript Biotech expects adjusted net profit from continuing operations for 2025 to surge to between US$207.3 million and US$241.9 million from US$59.8 million a year earlier, driven largely by a sharp rise in license revenue, notably sublicense income from LaNova Medicines. The company projects license revenue of US$256.1 million to US$298.8 million for the year, up from just US$2.4 million in 2024, underscoring strong momentum in its licensing business.

At the same time, heavy non-cash charges tied to its investment in Legend Biotech will push the group to a full-year loss of US$505.8 million to US$585.6 million, versus a prior-year profit inflated by a one-off unrealised gain from deconsolidating Legend. Genscript will book a substantial share of Legend’s losses and an impairment of US$378.2 million to US$437.9 million after a drop in Legend’s ADS price, though management highlights that Legend’s adjusted loss has narrowed significantly and reiterates confidence in its long-term prospects, with the group’s underlying profitability described as resilient once one-off and non-cash items are excluded.

The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

More about Genscript Biotech

Genscript Biotech Corporation is a Cayman Islands–incorporated biotech company listed in Hong Kong, operating in life sciences and cell therapy–related businesses. The group generates revenue from biotech products and services, including licensing income, and holds a significant associate stake in Nasdaq-listed Legend Biotech, reflecting a strategic focus on cell therapy innovation.

Average Trading Volume: 8,618,525

Technical Sentiment Signal: Sell

Current Market Cap: HK$25.41B

See more data about 1548 stock on TipRanks’ Stock Analysis page.